SODIUM CHLORIDE 0.9%
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Isotonic solution of sodium chloride provides replacement of sodium and chloride ions, maintains extracellular fluid volume, and serves as a vehicle for drug administration. It acts as a source of electrolytes and water for hydration.
| Metabolism | Sodium chloride is not metabolized; it distributes in extracellular fluid and is excreted primarily by the kidneys. |
| Excretion | Renal excretion; >99% of filtered sodium and chloride are reabsorbed under normal physiological conditions, with excretion equal to intake. In clinical use, excess sodium and chloride are excreted renally. Biliary/fecal excretion is negligible (<1%). |
| Half-life | Not applicable; sodium and chloride are endogenous electrolytes. Their half-life depends on renal function and volume status, typically ranging from 6 to 12 hours in healthy individuals, but prolonged in renal impairment. |
| Protein binding | Sodium and chloride are not protein-bound; <1% bound to proteins. |
| Volume of Distribution | 0.6-0.7 L/kg; sodium and chloride distribute primarily in extracellular fluid (approx. 20% of body weight) with minimal intracellular penetration. Vd approximates extracellular fluid volume. |
| Bioavailability | Intravenous: 100%. Oral: 100% for absorbed dose, but absorption is limited by gastrointestinal tolerance and regulatory mechanisms. |
| Onset of Action | Intravenous: Immediate (within seconds to minutes) for plasma volume expansion; absorption from gastrointestinal tract occurs within minutes for oral administration. |
| Duration of Action | Intravenous: Duration depends on distribution and renal excretion; plasma volume expansion lasts 30-60 minutes. Continuous infusion maintains effect as long as infused. |
Intravenous infusion, typical adult dose: 500-1000 mL bolus for volume resuscitation, then rate determined by clinical status; maintenance: 100-200 mL/hour continuous IV infusion.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required due to impaired GFR; however, monitor for fluid overload and hypernatremia in renal impairment. Use with caution in patients with GFR <30 mL/min. |
| Liver impairment | No adjustment required for hepatic impairment; Child-Pugh classification does not alter dosing. |
| Pediatric use | Intravenous infusion: 10-20 mL/kg bolus for shock, repeat as needed based on clinical response; maintenance: 100-150 mL/kg/day for first 10 kg, then 50 mL/kg/day for next 10 kg, then 20 mL/kg/day for remaining weight. |
| Geriatric use | Lower initial rates recommended due to decreased renal function and increased risk of fluid overload; typical maintenance rate: 75-125 mL/hour continuous IV infusion, titrate to clinical response and monitoring of electrolytes and volume status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Safe during breastfeeding. Sodium chloride is a normal constituent of breast milk. M/P ratio not applicable as exogenous administration does not significantly alter milk sodium levels. |
| Teratogenic Risk | Sodium Chloride 0.9% is considered low risk for teratogenicity. No evidence of structural anomalies in first trimester. Second and third trimester use is safe; caution in preeclampsia due to potential fluid overload. |
■ FDA Black Box Warning
None
| Common Effects | fluid replacement |
| Serious Effects |
["Hypernatremia","Fluid overload","Hypersensitivity to sodium chloride"]
| Precautions | ["Use with caution in patients with hypertension, heart failure, renal impairment, or edema","Risk of fluid overload causing pulmonary edema","Hypersensitivity reactions (rare)","Monitor serum electrolytes, especially in prolonged use"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs, serum electrolytes, urine output, and signs of fluid overload. In pregnancy, especially in preeclampsia or renal impairment, assess for edema and pulmonary congestion. Fetal heart rate monitoring if maternal condition unstable. |
| Fertility Effects | No known adverse effects on fertility. |